Hallucinations and other psychotic symptoms in response to methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder: a Cochrane systematic review with meta-analysis and trial sequential analysis by Ramstad, Erica et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Hallucinations and other psychotic symptoms in response to methylphenidate in
children and adolescents with attention-deficit/hyperactivity disorder: a Cochrane
systematic review with meta-analysis and trial sequential analysis
Ramstad, Erica; Storebø , Ole Jakob; Gerner, Trine; Krogh, Helle B; Holmskov, Mathilde;
Magnusson, Frederik Løgstrup; Moreira-Maia, Carlos R; Skoog, Maria; Groth, Camilla; Gillies,
Donna; Zwi, Morris; Kirubakaran, Richard; Christian, Gluud; Simonsen, Erik
Published in:
Scandinavian Journal of Child and Adolescent Psychiatry and Psychology
DOI:
10.21307/sjcapp-2018-003
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Citation for published version (APA):
Ramstad, E., Storebø , O. J., Gerner, T., Krogh, H. B., Holmskov, M., Magnusson, F. L., ... Simonsen, E. (2018).
Hallucinations and other psychotic symptoms in response to methylphenidate in children and adolescents with
attention-deficit/hyperactivity disorder: a Cochrane systematic review with meta-analysis and trial sequential
analysis. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology, 6(1), 52-71.
https://doi.org/10.21307/sjcapp-2018-003
Download date: 03. Feb. 2020
 52 
 
Scandinavian Journal of Child and Adolescent Psychiatry and Psychology 
Vol. 6(1):52-71 (2018) DOI 10.21307/sjcapp-2018-003 
 
 
Review Open Access 
 
 
 
 
Hallucinations and other psychotic symptoms in response to 
methylphenidate in children and adolescents with attention-
deficit/hyperactivity disorder: a Cochrane systematic review with 
meta-analysis and trial sequential analysis# 
 
Erica Ramstad1,2*, Ole Jakob Storebø,2,3, Trine Gerner1, Helle B. Krogh1,2, Mathilde Holmskov1, 
Frederik L. Magnusson1, Carlos R. Moreira-Maia4, Maria Skoog5, Camilla Groth6, Donna Gillies7, 
Morris Zwi8, Richard Kirubakaran9, Christian Gluud5,10, Erik Simonsen1,11 
 
 
1Psychiatric Research Unit, Region Zealand, Slagelse, Denmark; 
2Child and Adolescent Psychiatric Department, Region Zealand, Denmark; 
3Department of Psychology, Faculty of Health Science, University of Southern Denmark, Odense, Denmark; 
4Federal University of Rio Grande do Sul, Porto Alegre, Brazil; 
5Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet,  
Copenhagen University Hospital, Copenhagen, Denmark; 
6Pediatric Department E, Herlev University Hospital, Herlev, Denmark; 
7Western Sydney Local Health District; Mental Health, Parramatta, Australia; 
8Islington CAMHS, Whittington Health, UK; 
9Cochrane South Asia, Prof. BV Moses Center for Evidence-Informed Health Care  
and Health Policy, Christian Medical College, Vellore, India; 
10The Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, 
Department 7812, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; 
11Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark 
 
 
*Corresponding author: erica_ramstad@hotmail.com 
 
#This article is based on two Cochrane Reviews: ”Methylphenidate for children and adolescents with attention deficit hyperactivity 
disorder (ADHD)” is published in the Cochrane Database of Systematic Reviews (CDSR) 2015, Issue 11, DOI: 
10.1002/14651858.CD009885.pub2 (see www.thecochranelibrary.com for information) and ”Methylphenidate for attention deficit 
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Abstract 
 
Background: There is little evidence in the literature on the association between methylphenidate treatment and psychotic 
symptoms in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).  
Objective: We examine the occurrence of psychotic symptoms during methylphenidate treatment of children and adolescents 
with ADHD. The data arise from our two Cochrane systematic reviews on methylphenidate, reported elsewhere.  
Methods: Electronic databases were searched up to January 2016 (for observational studies) and March 2017 (for randomized 
trials). We summarized data as risk ratios and pooled prevalences. Trial Sequential Analysis was used to control for random 
errors. We assessed the risk of bias and the quality of evidence according to Cochrane guidelines. 
Results: Ten randomized trials (1103 participants), 17 non-randomized studies (76,237 participants) and 12 patient reports 
or series (18 patients) were identified. In the randomized trials, there was no significant difference in the risk of developing 
psychotic symptoms [10 of 654 (pooled prevalence, 2.5%) methylphenidate versus 1 of 508 (pooled prevalence, 1.7%) placebo 
patients; risk ratio, 2.07; 95% confidence interval, 0.58 to 7.35]. Nine of 10 trials had a high risk of bias, and according to the 
Trial Sequential Analysis, the required information size was not achieved, that is, the meta-analysis was considerably 
underpowered. There were 873 instances of psychotic symptoms in the non-randomized studies among 55,603 participants 
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(pooled prevalence, 1.2%; 95% confidence interval, 0.7 to 2.4). In the comparative cohort study, methylphenidate significantly 
increased the risk for any psychotic disorder by 36% (risk ratio, 1.36; 95% confidence interval, 1.17 to 1.57). The overall risk 
of bias was rated as critical for this study. 
Conclusions: Because of sparse data and low quality of evidence, we cannot confirm or refute whether methylphenidate 
increases the risk of psychotic symptoms in children and adolescents with ADHD. This possible adverse event may affect 
1.1% to 2.5%, and physicians, patients and caregivers should be aware of this to ensure proper treatment in case of occurrence 
during methylphenidate treatment.  
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Introduction 
Attention-deficit/hyperactivity disorder (ADHD) is 
a neurodevelopmental disorder with a worldwide 
prevalence of around 5.3% among children and 
adolescents (1). The diagnosis is made by a clinical 
evaluation of whether a child has presented excessive 
inattention, hyperactivity and impulsivity. These 
must be present before six years [International 
Statistical Classification of Diseases and Related Health 
Problems, 10th Revision (ICD-10)] or 12 years 
[Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition (DSM-5)] and impairing his or her 
functioning and/or development. ADHD symptoms 
may persist into adulthood and 15% of the patients 
continue to fulfil the full criteria for ADHD at the 
age of 25 (2,3). Psychostimulants, including 
methylphenidate, are the recommended first-choice 
drug treatment for ADHD (4-7). Because so many 
children and adolescents are prescribed methyl-
phenidate (8-10), it is important that the risk of 
adverse events is better understood.  
By definition, a substance/medication-induced 
psychotic disorder must be present during treatment 
or appear soon after withdrawal (DSM-5), within 2 
weeks [ICD-10 (F15.5)] or a month (DSM-IV-TR) 
depending on the diagnostic criteria used. Psychosis 
reflects an experience of impaired reality through 
symptoms such as hallucinations and delusions. 
However, psychotic symptoms are not always 
associated with a psychotic disorder and can occur in 
individuals who have an awareness that their 
experience does not reflect reality (11).  
Psychotic symptoms have been reported in 
children and adolescents with ADHD prescribed 
methylphenidate in clinical trials and as patient 
reports (12). Clinical guidelines recommend a 
reduction or a withdrawal of methylphenidate if 
psychotic symptoms occur (13,14) and caution in 
prescribing methylphenidate in patients with a 
history of psychotic episodes or a family history of 
psychotic disorder (15).  
To the best of our knowledge, no systematic review 
of the literature specifically examining psychotic 
symptoms in relation to methylphenidate use has 
been performed.  
Three publications provide evidence- and expert-
based guidance on ADHD medication adverse 
events, including psychotic symptoms (4,15,16). All 
three publications are largely based on the same 
meta-analyses carried out by the Food and Drug 
Administration (FDA) in 2006 to 2009 (12,17). The 
FDA examined the occurrence of psychotic 
symptoms and mania during drug therapy for 
ADHD (i.e., amphetamine, dextroamphetamine, 
atomoxetine, modafinil and methylphenidate) by 
reviewing clinical trial data as well as post-marketing 
spontaneous reports. Data were provided by 
manufacturers of ADHD medication and the FDA 
Adverse Event Reporting System safety database 
(12). The methodology used resulted in the exclusive 
inclusion of trials funded by pharmaceutical 
companies (12). Relevant trials conducted by 
independent research groups were not sought, and 
the restricted use of data sources could have 
influenced the data collection and ultimately the 
meta-analysis. Study selection of only industry-
sponsored trials could have created an additional risk 
of bias (18). Furthermore, the risk of random errors, 
risk of bias and trial methodological quality were not 
assessed systematically. Despite these limitations, the 
report noted the absence of psychosis and mania 
events in placebo-treated patients and therefore 
advised that drugs for ADHD may be associated with 
such symptoms (17). 
We have performed two Cochrane systematic 
reviews on the efficacy and safety of methylphenidate 
use in children and adolescents with ADHD, and we 
sought to avoid any methodological flaws and 
shortcomings (19-21). In the first review, we 
included randomized clinical trials (19). In the second 
review, we included observational studies, the 
methylphenidate group from randomized clinical 
trials without placebo or no intervention comparator 
group, follow-up periods from randomized clinical 
trials and patient reports (21).  
This article highlights one of the many safety 
outcomes in the two Cochrane publications (19-21) 
and attempts to establish whether psychotic 
symptoms occur as an adverse event to methyl-
phenidate treatment in randomized clinical trials and 
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observational studies of children and adolescents 
with ADHD. 
 
Methods 
The design and methodology of our study followed 
the Cochrane Handbook for Systematic Reviews of 
Interventions (22) and PRISMA guidelines (23,24), 
which we have described in the protocols (25,26). 
 
Data sources and search criteria 
The literature search was carried out and updated for 
the two Cochrane systematic reviews (19,21) up to 
February 2015. CINAHL, Cochrane Library, 
EMBASE, MEDLINE, PsycINFO, ISI CPCI 
databases, Clinical Trials and ICTRP were searched 
from origin without restrictions in terms of language, 
year of publication or type of publication (25,26). 
Review articles were searched for additional, 
potentially relevant references. Similarly, the 
bibliography of a sample of included articles was 
searched for additional studies. In January 2016, we 
updated the search for observational studies, and 
included a “grey literature” search. Unpublished data 
were also sought from the United States FDA and 
the European Medicines Agency (21). To collect all 
new relevant randomized clinical trials, the literature 
search for randomized clinical trials was updated in 
March 2017 for the present review.  
Where necessary, the authors of the articles 
included were contacted for additional data. Some 
authors provided additional, potentially relevant 
articles. Pharmaceutical companies were contacted 
for relevant published and unpublished data. Each 
step of the review was conducted by two review 
authors, apart from assessment and processing of the 
final literature search in March 2017, which was 
conducted by the first author. 
 
Participant inclusion criteria and study selection 
After removal of duplicates, authors screened titles 
and abstracts of the retrieved records. Full-text 
articles of records judged to be potentially relevant 
were assessed for eligibility according to our 
inclusion criteria. Eligibility criteria included children 
and adolescents with a diagnosis of hyperkinetic 
disorder or ADHD according to ICD or DSM 
diagnostic criteria, respectively (ICD-9, DSM-III and 
newer). At least 75% of the study participants had to 
be younger than 19 years and the mean age had to be 
younger than 19 years. We included trials irrespective 
of comorbidities, but at least 75% of the participants 
were required to have a normal intellectual capacity 
(IQ≥70 points). Study designs considered eligible for 
the assessment of safety were randomized clinical 
trials on methylphenidate with placebo or no 
intervention as a comparator, non-randomized 
studies and patient reports. Furthermore, the 
methylphenidate group from randomized clinical 
trials without placebo or no intervention comparator 
group as well as follow-up periods from randomized 
clinical trials were included in the observational study 
category (19,21). 
For inclusion in the present review, co-medication 
was only accepted as over-the-counter drugs or if the 
co-medication was identical in the intervention and 
the control group. 
 
Psychotic symptoms 
To obtain data on any psychotic phenomena, we 
included articles reporting assessment and/or 
occurrence of “psychosis”, “psychotic”, 
“hallucination” and “delusion”. Only reports of 
symptoms during methylphenidate treatment or up 
to a month after withdrawal qualified for inclusion in 
the present review. Formal assessment of psychotic 
symptoms was not mandatory, and we accepted both 
spontaneous reports as well as formal assessment, for 
example, the Pittsburgh Side Effect Rating Scale, 
which includes hallucinations as an item (27). 
 
Data extraction and quality assessment 
Data were extracted using a template to facilitate a 
standardized extraction method between researchers. 
In our analyses, reports of psychotic symptoms 
leading to withdrawal were not separated from 
reports of psychotic symptoms in the observed study 
population. The risk of bias in randomized trials was 
rated at the study level using the Cochrane 
Collaboration Handbook for Systematic Reviews 
(22). We defined low risk of bias trials as trials that 
had a low risk of bias in all domains. We considered 
trials with one or more unclear or high risk of bias 
domains as trials with a high risk of bias (25). This 
procedure was based on the fact that randomized 
clinical trials with an unclear or a high risk of bias 
tend to overestimate benefits and underestimate 
harms compared with trials with a low risk of bias 
(28-34). Risk of bias in non-randomized studies, that 
is, comparative cohort studies and patient–control 
studies with data, were rated using the ROBINS-I 
tool (Risk Of Bias In Non-randomized Studies - of 
Interventions) (35). We assessed and graded the 
evidence according to Grading of Recommendations 
Assessment, Development, and Evaluation 
(GRADE) for a high risk of bias, imprecision, 
indirectness, heterogeneity and publication bias (36). 
We report our methodology in greater detail in our 
Cochrane reviews (19,21). 
 
Data synthesis and statistical analysis 
Data from parallel group and cross-over trials were 
summarized as risk ratios with 95% confidence 
intervals using the inverse variance method. We 
combined data from cross-over trials and parallel 
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group trials. Because it might lead to a unit of analysis 
error, when cross-over trials are analysed as parallel 
group trials, we carried out a subgroup analysis of 
study designs. Whenever a cross-over trial reported 
data on psychotic symptoms in more than one of the 
groups exposed to methylphenidate, we combined 
the groups if the patients did not appear in more than 
one of the groups, otherwise we included data from 
the group with the highest dose exposure. 
Furthermore, we carried out a subgroup analysis for 
dose. For this, we defined low dosage treatment as 
≤20 mg/day or ≤0.6 mg/kg/day and moderate/high 
dosage treatment as >20 mg/day or >0.6 mg/kg/day 
(19). We also carried out a subgroup analysis on the 
type of methylphenidate formulation. Here, we 
compared immediate-release with extended-release 
inclusive osmotic release oral system and 
methylphenidate transdermal system. Furthermore, 
we planned to carry out subgroup analyses on 
comorbidity and sex. We carried out a sensitivity 
analysis on age by excluding studies including young 
adults defined as study participants older than 15 
years. We used the random-effect model as the 
primary method and the fixed-effect model as a 
sensitivity analysis (37). When carrying out a meta-
analysis, a required information size should be 
estimated to better identify whether an apparent lack 
of effect may be because of inadequate data just as 
an a priori sample size calculation is performed for a 
single randomized clinical trial (38,39). For this, we 
used Trial Sequential Analysis, which combines the 
calculation of a required information size with trial 
sequential monitoring thresholds for benefit, harm or 
futility (39-41). Furthermore, we planned to assess 
whether there may be publication bias among 
randomized clinical trials by testing for funnel plot 
asymmetry.  
Data from comparative cohort studies were 
summarized as risk ratios with 95% confidence 
interval using the inverse variance method. The 
occurrence of psychotic symptoms was calculated as 
pooled prevalences with 95% confidence intervals in 
six analyses. We report the pooled prevalence for the 
methylphenidate and the placebo group in the 
randomized clinical trials separately, the non-
randomized studies and a “grand total” of all non-
randomized studies and the methylphenidate group 
in randomized clinical trials. Furthermore, the pooled 
prevalence was calculated for two of the study 
designs included in the non-randomized study 
category, that is, cohort studies and the 
methylphenidate group in randomized clinical trials 
without placebo or no intervention comparator. We 
also calculated the pooled annual incidence of 
psychotic symptoms in non-randomized studies.  
Data from patient reports were reported 
qualitatively, that is, number of patients experiencing 
psychotic symptoms and type of psychotic symptom. 
Data were analysed using the program 
Comprehensive Meta Analysis (42) and the software 
Review Manager (43). 
 
Results 
A total of 14,334 records were retrieved in the 
literature searches, and 2736 records were considered 
potentially eligible after screening. After full-text 
assessments of these 2736 records, 80 articles 
describing 27 studies (10 randomized trials and 17 
non-randomized studies) and 12 patient reports or 
series were included in the present review (Figure 1). 
Two studies were included on the basis of their 
published protocols; however, the results of the 
studies have still not been published (44,45). No data 
on psychotic symptoms were obtained from 
unpublished trials. Four hundred and twelve studies 
included in the Cochrane reviews on the efficacy and 
safety of methylphenidate (from the literature 
searches up to January 2016) did not report 
assessment or occurrence of psychotic symptoms. 
 
Included studies 
We included 10 randomized clinical trials [four 
parallel group trials (46-50) and six cross-over trials 
(51-57)] totalling 1103 participants, 17 non-
randomized studies (49,58-75) totalling 76,237 
participants and 12 patient reports or small series 
describing 18 patients (76-88). 
 
Randomized clinical trials 
Table 1 shows the characteristics of the included 
studies, that is, number, age, sex and 
methylphenidate-naïvety of the participants; 
methylphenidate type, dose and dosage regimen; 
assessment; and type and number of psychotic 
symptoms. Two trials were designed as summer 
treatment programs (52,53), one trial used a 
laboratory classroom design (54) and the remaining 
were carried out in outpatient settings. Five trials 
excluded patients with comorbid psychotic disorder, 
schizophrenia or similar diagnoses (46,47,50,54,55). 
Two trials only included participants with 
comorbidity, that is, velocardiofacial syndrome (49) 
and non-nicotine substance use disorder (50). One 
trial excluded patients with a history of serious 
adverse reactions to methylphenidate or lack of 
response to methylphenidate (54).  
The median age for the randomized trials was 9.50 
years and the interquartile range was 8.70 to 10.50 
years. Across trials, 26% to 100% of the participants 
were diagnosed with ADHD combined subtype, 
20% to 74% with the inattentive subtype, and 0% to 
4% with the hyperactive-impulsive subtype. All 
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randomized clinical trials used placebo as a 
comparator. Three of the six cross-over trials 
switched interventions daily (52,53,55) and only one 
cross-over trial included a wash-out period between 
the interventions (51). Six of the 10 randomized trials 
used rating scales including an item focusing on 
psychotic symptoms, that is, visual and auditory 
hallucinations (47,51-53,55,56), two trials assessed 
serious adverse effects without further specification 
(46,50) and two trials recorded spontaneous reports 
(49,54).  
 
 
 
 
 
FIGURE 1. PRISMA flow diagram (24) 
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TABLE 1. Characteristics of included randomized clinical trials 
 
Study ID, country Study 
design 
N Age range 
Mean (SD) 
(years) 
Male 
[n (%)] 
MPH-naïve 
[n (%)] 
MPH type, mean daily dose 
Dosage regimen 
Time of MPH 
intervention 
Mode of assessment Type and number of 
psychotic events 
Becker 
2016/Froehlich 
2015, USA 
Cross-
over 
163 7-11 
8.41 (1.24) 
117 (72) 163 (100) MPH-OROS 
<25 kg: 18/27/36 mg 
>25 kg: 18/36/54 mg 
Once daily 
3 weeks Pittsburgh Side Effect 
Rating Scale, Parent 
rated 
Hallucination  
Placebo: n=0/163 
18 mg: n=1/163 
27 mg: n=1/31 
36 mg: n=4/163 
54 mg: n=5/132 
Buitelaar 1996, 
The Netherlands 
Cross-
over 
52 6-13 
9.29 (1.63) 
46 (88) 52 (100) 
 
MPH-IR, 20 mg 
Twice daily (at breakfast and at 
noon) 
4 weeks Modified Stimulant Drug 
Side Effects Rating scale, 
Parent rated 
Interim analysis 
Hallucination: n=1 
Childress 2009, 
NCT-00301236, 
USA 
Parallel 253 6-12 
8.7 (1.84) 
163 (64) 175 (69) 
 
MPH-ER, 10/20/30 mg 
(3 parallel groups) 
Once daily in the morning 
5 weeks Regular monitoring of 
serious adverse events 
Tactile hallucination: 
n=1 (30 mg) 
Palumbo 
2008/Daviss 2008, 
NCT-00031395, 
USA 
Parallel 122 7-12 
9.5 (1.6) 
98 (80) 57 (47) MPH-IR, 30.2 mg 
1 to 3 times daily (in the 
morning, noon and at 4 p.m.) 
12 weeks Pittsburgh Side Effect 
Rating Scale, Parent and 
teacher rated. 
Spontaneous self-
reports. 
Groups without co-
intervention 
hallucination: n=0/59 
Green 2011, NCT-
00768820, Israel 
Parallel 34 5-20 
11.1 (3.7) 
20 (59) 21 (62) MPH-IR, 15.7 mg 
1 dose 
1 day Spontaneous reports Psychotic symptoms: 
n=0 
Pelham 1999, 
USA, Summer 
Treatment 
Program 1988 
Cross-
over 
21 6-12 
10.3 (1.9) 
19 (90) 
 
7 (33) 
 
MPH-IR, 0.9/0.75/0.3 mg/kg 
1 to 3 times daily (morning, noon 
and afternoon at 3:30 p.m.) 
 
1 day×3 
(placebo: 2 
days×3) 
Pittsburgh Side Effect 
Rating Scale. Parent, 
teacher, and counselor 
rated 
Hallucination: n=1 
Pelham 2005, 
USA, Summer 
Treatment 
Program 
Cross-
over 
36 6-13 
9.6 (NA) 
33 (92) 26 (72) MTS, 0.45/0.9/1.8 mg/h 
Worn at least 12 hours daily 
Application time once daily (at 6 
or 7 a.m.) 
1 day×2 Pittsburgh Side Effect 
Rating Scale. Parent, 
teacher, and counselor 
rated 
Hallucination: n=0 
Riggs 2011, NCT-
00264797, USA 
Parallel 303 13-18 
16.5 (1.3) 
239 (79) NA MPH-OROS, 68 mg 
Once daily in the morning 
16 weeks Systematic assessment 
of serious adverse 
events 
Psychotic disorder: 
n=1 
Schachar 2008, 
USA 
Cross-
over 
18 6-15 
11.3 (2.2) 
15* (88) NA MPH-IR or 
MPH-ER, 31.2 mg 
1 to 2 times daily (morning- and 
lunch-time dose) 
1 week Spontaneous reporting Psychosis: n=1 
Waxmonsky 2008, 
NCT-00050622, 
USA, Summer 
Treatment 
Program 
Cross-
over 
101 5-12 
8.35 (2.05) 
82 (81) NA MPH-IR, 15/30/54 mg 
Thrice daily (7:45 a.m., 11:45 
a.m. and 3:45 p.m.) 
1 day×3–4×3 Pittsburgh Side Effect 
Rating Scale. Staff and 
parent rated 
NA 
ER, extended-release; MPH, methylphenidate; MTS, MPH transdermal system; n, study participants; NA, not available; OROS, osmotic release oral system; IR, immediate-release  
*The sex of one patient is not stated  
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FIGURE 2. Risk ratio of nine randomized clinical trials comparing methylphenidate versus placebo for patients with ADHD. 
The following risk of bias items were rated as low (green), unclear (yellow) or high risk of bias (red): A: Random sequence generation (selection bias). 
B: Allocation concealment (selection bias). C: Blinding of participants and personnel (performance bias). D: Blinding of outcome assessment (detection 
bias). E: Incomplete outcome data (attrition bias). F: Selective reporting (reporting bias). G: Vested interest. C and D are for a number of trials assessed 
as without risk of bias, but because of prevalent and easily recognizable adverse events of methylphenidate, this assessment may well be wrong (19). 
CI, confidence interval; IV, inverse variance; MPH, methylphenidate; Random, random-effect model. 
 
 
 
Figure 2 presents the forest plot of the meta-analysis 
of randomized clinical trials. Only one of 10 trials 
was rated as having a low risk of bias (56). The 
remaining trials were rated as having a high risk of 
bias because of vested interest and inadequate 
information to assess whether the method used 
could induce bias (see Figure 2). The quality of 
evidence from the randomized clinical trials assessed 
according to GRADE guidelines was low owing to a 
high risk of bias and imprecision.  
The meta-analysis yielded 10 of 654 (pooled 
prevalence, 2.5%; 95% confidence interval, 1.4 to 
4.3) methylphenidate patients versus 1 of 508 
(pooled prevalence, 1.7%; 95% confidence interval, 
0.7 to 4.0) placebo patients with psychotic symptoms 
(risk ratio, 2.07; 95% confidence interval, 0.58 to 
7.35) (see Figure 2). The authors of one trial (55) 
reported assessment of hallucinations, but data were 
not available and therefore only nine trials were 
included in the meta-analysis.  
Findings using a fixed-effect model were similar 
(risk ratio, 2.07; 95% confidence interval, 0.58 to 
7.35). The combination of data from parallel group 
and cross-over trials was tested in a subgroup analysis 
(see Figure 2), and no significant difference was 
found between the parallel group trials (risk ratio, 
1.78; 95% confidence interval, 0.19 to 16.96) and the 
cross-over trials (risk ratio, 2.22; 95% confidence 
interval, 0.48 to 10.28), and the degree of 
inconsistency across trials in the analysis was 0%. 
The only reported psychotic episode in the placebo 
group was in a cross-over trial without any wash-out 
period between interventions (54). A sensitivity 
analysis was carried out without this trial (54), but the 
results were comparable (risk ratio, 2.96; 95% 
confidence interval, 0.74 to 11.81). Furthermore, we 
carried out subgroup-analyses for methylphenidate 
dose and formulation, but there was no statistical 
difference between low and moderate/high dose of 
methylphenidate groups: p=0.95 (Figure 3) or 
between methylphenidate immediate-release and 
methylphenidate extended-release/osmotic release 
oral system/transdermal system: p=0.60. The 
sensitivity analysis of age yielded comparable results 
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with (risk ratio, 2.07; 95% confidence interval, 0.58 
to 7.35) and without trials including young adults 
(49,50) (risk ratio, 1.93; 95% confidence interval, 0.49 
to 7.67). 
 
 
 
 
 
 
 
 
 
FIGURE 3. Risk ratio of nine randomized clinical trials comparing methylphenidate versus placebo. Subgroup analysis of dose. Low dose: ≤20 mg/day 
or ≤0.6 mg/kg/day methylphenidate. Moderate/high dose: >20 mg/day or >0.6 mg/kg/day methylphenidate. CI, confidence interval; IV, inverse 
variance; MPH, methylphenidate; Random, random-effect model. 
 
 
 
We used Trial Sequential Analysis to control the 
risks of random errors because of sparse data. We 
calculated the diversity-adjusted required 
information size by using data from the four parallel 
group trials that were able to provide data (649 
participants), a type 1 error of 5%, a type 2 error of 
20%, an assumed control group risk of psychotic 
symptoms of 2%, a relative risk reduction or increase 
of 50% and the diversity of the meta-analysis (0%) 
(Figure 4). With these variables, the diversity-
adjusted required information size was 4639 
participants, and the meta-analysis is thus 
considerably underpowered, having only achieved 
14.0% (649/4639) of the diversity-adjusted required 
information size. The unadjusted conventional 
intervention effect estimate was 1.77 (95% 
confidence interval, 0.16 to 19.35) using a constant 
of 0.5 for zero event handling. The Trial Sequential 
Analysis-adjusted confidence interval, however, 
ranged from 0.00 to 30,803. 
Non-randomized studies 
Seven of the 17 non-randomized studies were 
prospective cohort studies (60,63,65-67,71,72,74,75). 
Three studies were randomized clinical trials without 
placebo or no-intervention comparators and 
therefore assessed as prospective cohort studies by 
only including the methylphenidate groups 
(58,59,70). One study was a follow-up of a 
randomized clinical trial where all participants 
continued methylphenidate treatment, and, 
therefore, the follow-up period was assessed as a 
prospective cohort study (49). There were four 
retrospective cohort studies (61,62,64,73), of which 
one was a comparative cohort study (73). One 
retrospective self-controlled patient series study 
design was included, where psychotic events among 
patients during periods with no drug exposure were 
compared with psychotic events during 
methylphenidate treatment periods (69). One cross-
sectional study was included (68). 
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FIGURE 4. Trial Sequential Analysis of parallel group trials. The diversity-adjusted required information size to demonstrate or reject a relative risk 
reduction or an increase of 50% with a control group risk of psychotic symptoms of 2%, an alpha of 5%, a beta of 20% and a diversity of 0% is 4639 
patients (red vertical dashed line). The red vertical lines to the left represent the trial sequential monitoring boundaries for benefit and harm and the 
red dashed outward-sloping lines to the right represent the futility boundaries. The horizontal solid blue line is the cumulative Z-curve, showing that 
only 14.0% (649/4639) of the diversity-adjusted required information size has been accrued. a, alpha; b, beta; D, diversity; DARIS, diversity-adjusted 
required information size; RRR, relative risk reduction. 
 
 
 
Study characteristics are presented in Table 2. All 
studies were carried out in outpatient clinics, except 
one study, which only included hospitalized patients 
(64). Comorbid schizophrenia, psychotic disorder or 
psychiatric disorder were exclusion criteria in two-
thirds of the studies (58–60,63,65,66,70,71,73-75). 
Five studies only included patients with comorbid 
disorders, including schizophrenia (64), comorbid 
conduct disorder or oppositional-defiant disorder 
(59), severe mood dysregulation (60), sleeping 
difficulties (58) and velocardiofacial syndrome (49). 
One study only included patients with parents with 
severe mental illness (68). In the studies, 17.4% to 
100% of the patients had the ADHD combined 
subtype, 11.6% to 70.2% had the inattentive subtype 
and 0.8% to 55% had the hyperactive-impulsive 
subtype. The median age for the non-randomized 
studies was 9.50 years and the interquartile range was 
9.20 to 10.49 years. 
The assessment of psychotic symptoms varied 
across studies. Rating scales including items focusing 
on psychotic symptoms were used in two studies 
(60,68). In one of these studies, structured interviews 
for prodromal syndrome was also used (68). A 
structured form including any psychiatric 
symptomatology was used in one study (62). In two 
database studies, a diagnostic code of schizophrenia 
spectrum disorders, psychotic disorders or 
hallucination was used (69,73). In the rest of the 
studies, the assessment varied from a systematic 
assessment of adverse events without further 
specification to recording of spontaneous reports. 
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TABLE 2. Characteristics of included non-randomised studies 
 
Study ID, country N Age range 
mean (SD) 
(years) 
Male  
[n (%)] 
MPH-
naïve  
[n (%)] 
MPH type, mean daily dose 
Dosage regimen 
Time of 
intervention 
Mode of assessment Type and number of psychotic events 
Ashkenasi 2011, 
NCT00989950, USA 
26 6-12 
9.3  
(1.95) 
19  
(73) 
NA MTS, 10  max 30 mg (optimal dose) 
Applied once daily in the morning 
Worn for 9, 10, 11, and 12 h/day in 1 week 
each 
Titration 
+4 weeks 
maintenance 
Spontaneous reporting Withdrawal due to hallucinations n=1 
Arnold 2015, TOSCA 
study, 
NCT00796302,USA 
168 6-12 
8.89 
(2.01) 
129 
(77) 
NA MPH-OROS, 
 44.8 mg 
Once daily 
3 weeks titration 
+6 weeks 
maintenance 
NA Hallucinations n=0/156 in 3 weeks 
(0/70 in 9 weeks) 
Delusions n=0/156 in 3 weeks (0/70 in 9 
weeks) 
Baweja 2016,USA NA NA 
NA 
(NA) 
NA NA MPH*, NA 
NA 
6 weeks Pittsburgh Side Effects 
Rating Scale 
Hallucinations n=NA 
Cherland 1999, 
Canada 
98 4-17 
NA 
(NA) 
NA NA 
 
MPH*, NA 
Dose range: 5-80 mg 
NA 
21 months Spontaneous reporting Psychotic effects n=7/96 
Cortese 2015,Italy 1426 6-18 
10.55 
(2.75) 
1247  
(87) 
NA MPH-IR, 18.3 mg 
2-3 times daily 
up to 5 years A structured form 
including any psychiatric 
symptomatology 
Hallucination n=2 
Didoni 2011, Italy 34 6-17 
10.7 
(2.7) 
28  
(82) 
34 (100) MPH-IR, 39.9 mg 
2-3 times daily. 
> 1 year Parents were requested 
in advance to report any 
adverse events during 
follow-up visits 
Psychotic symptoms n=0 
Elman 1998, Israel 5 NA 
NA 
(NA) 
NA 
 
NA 
 
MPH*, NA 
NA 
NA NA n=0 
Findling 2009, NCT-
00151957, USA 
326 6-12 
9.2 
(1.9) 
212  
(65) 
~ 0 (~ 
0) 
MTS, 10152030 mg 
Applied once daily (~7 am) 
Worn for ~9 hours (~4 pm) 
12 months Systematic assessment Psychosis/mania n=3 
Green 2011, NCT-
00768820, Israel 
16 5-20 
NA 
(NA) 
NA 0 (0) 
 
MPH*, NA 
NA 
6 months Spontaneous reports Psychotic symptoms n=0 
Lee 2013/NA 2013, 
Republic of Korea, 
NCT01060150 
55 
 
12-18 
14.33 
(1.54) 
43  
(78) 
 
NA 
 
MPH-OROS, 45.78 mg 
Once daily 
12 weeks Adverse event checklist 
and general questioning 
Hallucination n=0/55 
 
121 12-18 
13.8 
(1.49) 
93  
(77) 
NA 54.53 mg 
Once daily 
12 weeks Adverse event checklist 
and general questioning 
Withdrawal due to hallucinations 
n=1/121 
MacKenzie 2016, 
Canada 
141 
+MPH:NA 
6-21 
NA 
(NA) 
67  
(48) 
NA MPH*, NA 
NA 
>12 months Schizophrenia proneness 
instrument-child and 
youth version 
and structured interview 
for prodromal syndrome 
Psychotic symptoms:  
Patients, +mph: n=6/NA 
Control, -mph: n=4/16 
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(continued) 
 
        
Man 2016, Hong Kong 76 6-19 
NA 
(NA) 
NA NA MPH-IR and –ER, NA 
NA 
Mean: 2.17 years Psychotic disorder or 
hallucination diagnostic 
code in the Clinical Data 
Analysis and Reporting 
System 
Baseline period (no drug): n=NA 
Exposed period: n=NA 
Mohammadi 2004, 
Iran 
16 6-14 
8.87 
(2.47) 
11  
(69) 
16 (100) 
 
MPH*, 1 mg/kg 
NA 
6 weeks NA Hallucination, delusion n=0 
Remschmidt 
2005/Hoare 2005, UK 
and Germany 
89 6-16 
NA 
(NA) 
NA 0 (0) MPH-OROS, 18, 36 or 54 mg 
Once daily 
1 year NA Delusion n=1 (18 mg) 
Shyu 2015, Taiwan ADHD: 
73,049 
 
ADHD+MP
H: 
53,600 
(73%) 
NA 
9.4 
(3.3) 
58,293  
(80) 
NA MPH*, NA 
NA 
5 months – 12 
years 
Schizophrenia spectrum 
disorders based on 
insurance status, 
outpatient and 
hospitalization claims 
databases 
Psychotic disorder: 
+MPH: 856/52,646 (1.6%) 
-MPH: 229/19,125 (1.2%) 
Schizophrenia: 
+MPH: 452/52,752 (0.9%) 
-MPH: 120/19,119 (0.6) 
Su 2015, China 239 6-16 
9.2 
(2.02) 
203  
(85) 
NA MPH-OROS, 18 36 54 mg 
Once daily 
8-week titration 
phase 
Treatment-emergent 
adverse events were 
recorded throughout the 
study 
Hallucination n=1 
Wilens 2005, USA 407 6-13 
9.2 
(1.8) 
338  
(83) 
0 (0) MPH-OROS, 35.244.2 mg 
Once daily 
21-24 months Systematic assessment, 
parent rated 
Withdrawal due to hallucinations n=1 
Note. , titrated to; MPH, methylphenidate; MTS, MPH transdermal system; n, study participants; NA, not available; OROS, osmotic release oral system; IR, immediate-release.  
*Type of methylphenidate formulation not available  
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FIGURE 5. Prevalence of psychotic symptoms in non-randomized studies.  
CI, confidence interval 
 
 
In the non-randomized studies included, 873 
instances of psychotic symptoms, including 
psychotic disorder, hallucinations, delusions and 
psychosis/mania, were reported to occur during 
methylphenidate treatment out of a total of 55,603 
patients (pooled prevalence, 1.2%; 95% confidence 
interval, 0.7 to 2.4) (Figure 5). The meta-analysis was 
based on 14 studies as data from three studies were 
not available (60,68,69). There was no significant 
difference in the pooled prevalence in the cohort 
studies (1.1%; 95% confidence interval, 0.5 to 2.3) 
(61-67,71-75) compared with the methylphenidate 
group in the randomized clinical trials without 
placebo or no intervention comparator (1.9%; 95% 
confidence interval, 0.4 to 7.8) (58,59,70). The 
pooled annual incidence in the non-randomized 
studies was 2.2% (95% confidence interval, 0.2 to 
4.1) on the basis of 12 studies with a total of 54,172 
patients and 23,375.35 person-years because two 
studies did not report useable treatment durations 
(62,64). In the comparative cohort study, 
methylphenidate was associated with an increased 
risk for any psychotic disorder of 36% (risk ratio, 
1.36; 95% confidence interval, 1.17 to 1.57) (73). The 
overall risk of bias was rated as critical for this study 
(Table 3) (73). Risk of bias assessment was only 
possible for one included study, that is the 
comparative cohort study (73), since it is a 
prerequisite for using ROBINS-I that the studies are 
comparative (35). Non-comparative studies are of 
critical risk of bias mostly due to confounding factors 
and therefore we considered all these studies as of 
critical risk of bias. The quality of evidence assessed 
according to GRADE guidelines was low owing to 
study design and a critical risk of bias.  
The “grand total” pooled prevalence summarizing 
data from the non-randomized study category 
(58,59,61-67,70-75) and the methylphenidate group 
in the randomized clinical trials, that is, with placebo 
as a comparator (46-54,56,57), was 1.8% (95% 
confidence interval, 1.2 to 2.8). 
 
  
TABLE 3. Risk of bias in non-randomised studies 
 Shyu 2015 
Bias due to confounding Critical 
Bias in selection of participants into the study Moderate 
Bias in classification of interventions Moderate 
Bias due to deviations from intended    
interventions 
Critical 
Bias due to missing data Critical 
Bias in measurement of outcomes Serious 
Bias in selection of the reported result No information 
Risk of bias judgement Critical 
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TABLE 4. Characteristics of included patient reports 
 
Study ID, country N Age, 
(years) 
Sex MPH-naïve (n) MPH type, mean daily dose Time of 
intervention 
Type and number of 
psychotic events 
Aguilera-Albesa 2010, Spain 2 6 F NA 50% MPH-IR/50% MPH-ER, 
1020 mg 
Once daily 
4 days Hallucinations: n=2 
8 M NA MPH-ER, 18 mg 
Once daily 
2 days 
Coignoux 2009, France 1 14 M NA MPH-ER, 54 mg 
Once daily in the morning 
6 months Psychotic symptoms: 
n=1 
Fernández-Fernández 2011, 
Spain 
1 10 M 0 MPH-ER, 1.2 mg/kg 
Once daily 
1 week Psychosis: n=1 
Goetz 2011, Czech Republic 1 7 F 0 MPH-OROS, 18 mg 
Once daily 
2.5 months Hallucination: n=1 
Gross-Tsur 2004, Israel 3 7 M NA MPH*, 7.5 mg 
Once daily 
1 year Hallucinations: n=3 
12 M NA MPH*, 10 mg 
Once daily 
Short period 
7.5 M NA MPH*, 7.5 mg 
Once daily 
Months 
Halevy 2009, Israel 1 8 
 
M 1 MPH*, 10 mg 
NA 
Days Hallucination: n=1 
Herguner 2015, Turkey 1 6 M NA MPH-OROS, 18 mg† 
NA 
2 months Hallucination: n=1 
Irmak 2014, Turkey 1 9 M 1 MPH*, 1mg/kg 
NA 
NA Hallucination: n=1 
Porfirio 2011, Italy 1 11 
 
M 1 MPH-IR, 30 mg 
Twice daily 
3 years Hallucination: n=1 
Rashid 2007, USA 1 10 M 0 MPH-IR, 2030 mg 
Twice daily 
2 days Hallucination: n=1 
Shibib 2009, UK 4 14 F 1 MPH-ER, 30 mg 
Once daily 
4 months Psychosis: n=4 
Hallucinations: n=3-4 
8 M 1 MPH-IR, 520 mg 
Twice daily 
7 days 
10 M 0 MPH-ER, 3654 mg 
Once daily 
3 weeks 
14 M 0 MPH-ER, 18 mg 
NA 
24 hours 
Tomás Vila 2010, Spain 1 10 
 
M 0 50% MPH-IR/50% MPH-ER, 
30 mg 
NA 
2 weeks Hallucination: n=1 
Note. , titrated to; ER, extended-release; F, female; M, male; MPH, methylphenidate; n: study participants; NA, not available; IR: immediate-release; OROS, osmotic 
release oral system 
*Type of methylphenidate formulation not available 
†The hallucinations started when acetaminophen suspension (120 mg/day) was administered in addition to methylphenidate and resolved after withdrawal of 
acetaminophen 
 
 
 
Patient reports 
In the 12 patient reports describing 18 patients 
(Table 4), 57.9% had ADHD combined subtype, 
10.5% had the inattentive subtype and 5.3% had the 
hyperactive-impulsive subtype.  
Sixteen patients developed new psychotic 
symptoms during methylphenidate treatment and 
two patients experienced exacerbation of pre-
existing psychotic symptoms, that is, chronic pattern 
of partial somatic hallucinations (83) and comorbid 
schizotypal personality disorder and infantile 
psychosis (77). The newly developed psychotic 
symptoms reported were primarily hallucinations, 
including visual, auditory and tactile hallucinations. 
The duration of methylphenidate treatment until the 
development of psychotic symptoms varied from 1 
day to 3 years. Time from ingestion of 
methylphenidate to initiation of psychotic symptoms 
varied from 1 hour to 1 day. The duration of 
psychotic symptoms varied from 2 hours to 1 day, 
except for one patient, who had psychotic symptoms 
for 1 week coinciding with the co-administration of 
acetaminophen (88). The psychotic symptoms 
remitted upon methylphenidate withdrawal in 16 of 
16 patients. In two of four patients, a re-challenge 
with methylphenidate was followed by the 
recurrence of symptoms (80,81). Furthermore, eight 
patients were reported to be followed up between 3 
months and 3 years after the occurrence of psychotic 
symptoms (77,79,80,82,83,88), and only one patient 
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continued to have symptoms (77). At follow-up, he 
was still receiving methylphenidate and was 
diagnosed with schizophrenia.  
The quality of evidence from the patient reports 
assessed according to GRADE guidelines was very 
low owing to the study design. 
 
Discussion 
The data included here are a subset of data from the 
most comprehensive systematic reviews of 
methylphenidate to date (19,21). Despite this, 
relatively few studies assessed or reported psychotic 
symptoms.  
Only nine of 185 randomized clinical trials and 23 
of 259 non-randomized studies and patient reports 
of methylphenidate in children and adolescents with 
ADHD reported assessment of psychotic symptoms. 
One randomized clinical trial and six non-
randomized studies and patient reports of psychotic 
symptoms were identified from the updating search 
in March 2017. Psychotic symptoms in relation to 
methylphenidate treatment have occasionally been 
reported since 1967 (12) and because of the relatively 
infrequent reports in the literature, it is fair to assume 
that serious reporting bias exists. We sought to 
obtain supplemental data from published and 
unpublished trials through correspondence with 
pharmaceutical companies, without success. Because 
of the sparse number of trials included in the meta-
analysis, we did not construct a funnel plot. Psychotic 
symptoms only occurred in six randomized trials 
(two parallel, four cross-over) and therefore the test 
power would be too small to distinguish chance from 
real asymmetry (22). 
The evidence that our present results are based on 
is of low and very low quality according to our 
assessment following GRADE guidelines and may 
be prone to bias. 
Meta-analysis showed no difference in the risk of 
psychotic symptoms between the methylphenidate 
and the placebo groups in the randomized clinical 
trials (risk ratio, 2.07; 95% confidence interval, 0.58 
to 7.35). It is worth noting that the only episode of 
psychotic symptoms in the placebo group occurred 
in a cross-over trial without wash-out periods (54), 
which makes the event dubious. However, the 
sensitivity analysis without this trial showed 
comparable results. The combination of data from 
parallel and cross-over trials was tested in another 
subgroup analysis and no statistically significant 
difference was present. A sensitivity analysis on age 
excluding trials including study participants older 
than 15 years showed comparable results. A 
subgroup analysis on dose was carried out showing 
no statistically significant difference in the 
occurrence of psychotic symptoms in the low-dose 
group compared with the moderate/high-dose 
group. Similarly, a subgroup analysis of 
methylphenidate formulation showed no statistically 
significant difference between the methylphenidate 
immediate-release and the methylphenidate 
extended-release/osmotic release oral 
system/transdermal system. It was not possible to 
carry out subgroup analyses, involving diagnostic 
criteria, comorbidity or sex because of the limited 
available data. No data from the first period of cross-
over trials were available and thus could not be 
included in the Trial Sequential Analysis. Our meta-
analysis of parallel trials was considerably 
underpowered according to the Trial Sequential 
Analysis, having only achieved 14.0% of the 
diversity-adjusted required information size. The 
result of the Trial Sequential Analysis highlights that 
the absence of evidence of an association in our 
analysis is not evidence suggesting that no association 
exists. Our results are primarily based on trials at high 
risk of bias (9/10) and accordingly low-quality 
evidence. However, the high risk of bias ought not 
necessarily to be interpreted as adding uncertainty 
about the occurrence of the reported psychotic 
symptoms, but rather uncertainty about the low 
frequency of the occurrence. In fact, the high risk of 
bias, including vested interest, may be a reason for 
under-reporting of psychotic symptoms (18,28-34). 
Furthermore, psychotic symptoms during 
methylphenidate treatment might not be reported if 
it is not judged to be an adverse event, but rather a 
natural occurring phenomenon or symptoms of 
comorbidity. Reporting bias in the studies included 
would lead to an underestimation of the prevalence 
of psychotic symptoms. However, 412 studies 
included in the two Cochrane systematic reviews 
(19,21) did not report assessment or occurrence of 
psychotic symptoms and were excluded from this 
study. If psychotic symptoms were not reported 
because they did not occur, the exclusion of the 
studies might have led to an overestimation of 
prevalence.  
In the hope of finding supplemental important 
data to the randomized trials, we chose to include 
non-randomized studies. The risk of bias was critical 
in the one non-randomized study that could be rated 
(owing to study designs). This comparative cohort 
study showed a significantly increased risk of any 
psychotic disorder with methylphenidate (risk ratio, 
1.36; 95% confidence interval, 1.17 to 1.57). As the 
authors themselves speculate, the patients exposed to 
methylphenidate might have had a higher symptom 
severity than the patients not exposed to 
methylphenidate. An underlining psychotic disorder 
might develop in time, especially for the patient 
group with a higher symptom severity, and therefore 
might not have been caused by methylphenidate 
treatment, but rather the full development of the 
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disorder itself. Furthermore, because of the study 
design, the authors could not control for substance 
use disorders, which could have also confounded the 
results. Exposure to cannabis, alcohol and other 
psychoactive drugs is known to be associated with a 
significantly higher prevalence of subclinical 
psychosis (11). These limitations are difficult to avoid 
in non-randomized studies.  
The pooled prevalence of psychotic symptoms 
during methylphenidate treatment in the randomized 
clinical trials (2.5%; 95% confidence interval, 1.4 to 
4.3) was not different from the pooled prevalence in 
the non-randomized studies (1.2%; 95% confidence 
interval, 0.7 to 2.4). Estimates from both study 
designs were smaller than the reported prevalence in 
the general population [17% for children and 7.5% 
for adolescents (89)]. However, the same applied for 
the pooled prevalence in the placebo group in the 
randomized clinical trials (1.7%; 95% confidence 
interval, 0.7 to 4.0) and the prevalence in the group 
without methylphenidate exposure in the 
comparative cohort study (1.2%, 229/19,125). This 
might be explained by the way in which psychotic 
symptoms were evaluated. Nine of 27 studies 
included in our review used a structured form or 
rating scales, including items focusing on psychotic 
symptoms, that is, visual and auditory hallucinations. 
In the remaining studies, adverse events were 
assessed by general questioning or recording of 
spontaneous reports, which are both insufficient and 
inadequate. Only one study used structured 
interviews (68). Rating scales and structured 
interviews are much more sensitive than general 
questioning about adverse events and recording of 
spontaneous reports of adverse events, and the 
proportions reported here might therefore be 
underestimates of the true value. In the meta-analysis 
of prevalence in the general population (89), 
psychotic symptoms were assessed using clinical 
interviews and questions of whether the 
child/adolescent ever hears voices or sounds that no 
one else can hear. A clinical interview is the gold 
standard for assessing the presence and severity of 
psychotic symptoms, but is resource-demanding. 
Screening with self-report questionnaires entails a 
risk of overestimating the prevalence of psychotic 
symptoms because of a high rate of false positives 
(89). However, the above question on auditory 
hallucinations shows good sensitivity, specificity as 
well as positive and negative predictive value for 
psychotic symptoms in general (90), and ought to be 
included in adverse effect rating scales.  
The quality of patient reports is considered very 
low and by including patient reports in a review a 
trade-off is made between being all-inclusive and not 
knowing whether unreliable information is 
republished (22). Consequently, patient reports can 
hardly contribute to the causality, but might point 
towards an association. The percentage of 
methylphenidate-naïve participants varied 
considerably (0% to 100%) between studies and the 
duration of methylphenidate treatment to the 
occurrence of psychotic symptoms in patient reports 
varied from 1 day to 3 years. Accordingly, if 
psychotic symptoms occur as an adverse event, the 
available data do not suggest whether such symptoms 
occur in the short or long term.  
Genetic studies have shown a possible common 
heritability of ADHD and schizophrenia, but 
whether those findings can influence the occurrence 
of psychotic symptoms in methylphenidate users 
remain unclear. A Danish study reported an 
increased relative risk of 4.3 for schizophrenia in 
adults with ADHD compared with the general 
population (91). In a nationwide Taiwanese cohort, 
children with ADHD had an increased risk of 
developing any psychotic disorder (adjusted hazard 
ratio, 5.2) or schizophrenia (adjusted hazard ratio, 
4.65) compared with non-ADHD controls (73). A 
small but significant genetic susceptibility was found 
in rare chromosomal variants (92), but needs to be 
replicated. Similarly, genetic variations at SNAP25 
can be associated differentially with both psychiatric 
conditions (93). 
Approximately two-thirds (16/27) of the included 
studies, randomized as well as non-randomized, had 
comorbid psychotic disorders as an exclusion 
criterion, making the results less generalizable to 
ADHD patients with known susceptibility to 
psychotic symptoms. However, in a retrospective 
cohort study with five patients in a prodromal 
schizophrenic state, none developed psychotic 
symptoms in response to methylphenidate (64). In 
contrast, methylphenidate exacerbated psychotic 
symptoms in two patient reports (77,83). 
Methylphenidate mediates its effect through the 
dopaminergic and noradrenergic neurotransmitter 
systems, and increases the concentration of 
dopamine in the synaptic cleft (94). 
Hyperdopaminergic activity in patients with 
schizophrenia is believed to cause psychotic 
symptoms (95). Thus, one might believe that 
methylphenidate may unmask psychotic symptoms 
in genetically vulnerable patients through a 
synergistic mechanism. If this is so, the occurrence 
of psychotic symptoms during methylphenidate 
treatment in clinical studies, with the exclusion of 
these vulnerable patients, would not seem to reflect 
the occurrence of psychotic symptoms in the 
population of ADHD patients in a clinical setting.  
Results in relation to current knowledge 
This systematic review provides an overview of the 
existing literature and the results are in line with the 
FDA report (12). Psychotic symptoms occurring 
Methylphenidate and psychotic symptoms 
 
 
67 
 
during methylphenidate treatment may represent an 
adverse event. No significant difference in the risk of 
developing psychotic symptoms was present in the 
randomized clinical trials, but according to the Trial 
Sequential Analysis, the meta-analysis was 
considerably underpowered. In the included 
comparative cohort study, methylphenidate 
significantly increased the risk of any psychotic 
disorder by 36%. The prevalence of psychotic 
symptoms obtained in our review from the non-
randomized studies was much lower than the 
corresponding numbers for the general population 
and this was considered to be because of 
methodological differences, in particular, assessment 
strategy, but could also be because of bias and low 
quality of evidence.  
 
Implications for future research 
Future high-quality, long-term randomized placebo-
controlled trials assessing methylphenidate-induced 
psychotic symptoms concurrently with beneficial 
effects are needed and in particular trials with large 
sample sizes, inclusion of patients vulnerable to 
psychotic adverse events and assessment of 
psychotic symptoms by clinical interviews or 
standardized rating scales. Long duration of placebo 
administration and inclusion of patients vulnerable to 
psychotic adverse events might be ethically 
questionable and therefore also non-randomized 
studies may be of great importance.  
An adverse effect rating scale of methylphenidate 
should include assessment of psychotic symptoms, 
for example, a question of whether the 
child/adolescent ever hears voices or sounds that no 
one else can hear. Furthermore, the severity and 
implication for the child of psychotic symptoms 
ought to be assessed in a clinical interview as 
psychotic symptoms are not necessarily associated 
with a psychotic disorder (11).  
 
Conclusions 
Because of sparse data and low quality of evidence, 
we cannot confirm or refute whether 
methylphenidate increases the occurrence of 
psychotic symptoms in children and adolescents with 
ADHD. 
It seems that it is not possible to make definitive 
conclusions on the occurrence of psychotic 
symptoms in relation to methylphenidate because of 
methodological issues. A number of limitations are 
highlighted in the discussion, but the present review 
does have a number of strengths: it was conducted 
according to Cochrane guidelines, which involve 
thoroughness. Protocols were published before the 
reviews were conducted. The literature search was 
thorough and systematic, and pharmaceutical 
companies were contacted to obtain data from 
unpublished trials. We believe that our approach has 
led to the best possible gathering of relevant 
literature on the subject.  
The results of the meta-analyses in our main 
publication (19) suggest that methylphenidate 
treatment of children and adolescents with ADHD 
may improve ADHD symptoms, general behaviour 
and quality of life. However, the magnitude of the 
beneficial effects cannot be established because of 
the low quality of the evidence. Within the short 
study duration typical of the included trials, 
methylphenidate is associated with an increased risk 
of non-serious adverse events, such as sleep 
problems and decreased appetite, but because of 
sparse data, we could not determine whether 
methylphenidate increases the risk of serious adverse 
events (19). 
 
Clinical significance 
Psychotic symptoms may affect 1.1% to 2.5% of 
children, but there is inadequate evidence to 
determine that these are caused by methylphenidate 
treatment. Physicians, patients and caregivers should 
be aware of this possible adverse event to ensure 
proper treatment in case of occurrence during 
methylphenidate treatment. Concerns about this rare 
possible adverse event should be balanced against the 
potential beneficial effects of methylphenidate in 
children and adolescents with ADHD on ADHD 
symptoms, general behaviour and quality of life (19). 
Evidence supporting methylphenidate treatment of 
ADHD patients with a history of psychotic episodes 
is still awaited. 
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